Amino acids are sensitive glucagon receptor‐specific biomarkers for glucagon‐like peptide‐1 receptor/glucagon receptor dual agonists-Reference-Cited by-同舟云学术

Amino acids are sensitive glucagon receptor‐specific biomarkers for glucagon‐like peptide‐1 receptor/glucagon receptor dual agonists

Published:2020-09-23 Issue:12 Volume:22 Page:2437-2450
ISSN:1462-8902
Container-title:Diabetes, Obesity and Metabolism
language:en
Short-container-title:Diabetes Obes Metab

Author:

Li Wenyu¹,Kirchner Thomas¹,Ho George¹,Bonilla Fany¹,D'Aquino Katharine¹,Littrell James¹,Zhang Rui¹,Jian Wenying²,Qiu Xi²,Zheng Songmao³,Gao Bin⁴,Wong Peggy⁵,Leonard James N.¹,Camacho Raul C.¹^ORCID

Affiliation:

1. Cardiovascular Metabolism Discovery Janssen R&D Spring House Pennsylvania USA

2. Pharmacokinetics, Dynamics, and Metabolism Janssen R&D Spring House Pennsylvania USA

3. Janssen Biotherapeutics Janssen R&D Spring House Pennsylvania USA

4. Translational Medicine and Early Development Statistics Janssen R&D Spring House Pennsylvania USA

5. Quantitative Sciences Janssen R&D Raritan New Jersey USA

Publisher

Wiley

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/dom.14173

Reference60 articles.

1. Native Oxyntomodulin Has Significant Glucoregulatory Effects Independent of Weight Loss in Obese Humans With and Without Type 2 Diabetes

2. Oxyntomodulin Suppresses Appetite and Reduces Food Intake in Humans

3. Effect of Oxyntomodulin, Glucagon, GLP-1, and Combined Glucagon +GLP-1 Infusion on Food Intake, Appetite, and Resting Energy Expenditure

4. Subcutaneous Oxyntomodulin Reduces Body Weight in Overweight and Obese Subjects

5. Oxyntomodulin increases energy expenditure in addition to decreasing energy intake in overweight and obese humans: a randomised controlled trial

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Dose–response effects on HbA1c and bodyweight reduction of survodutide, a dual glucagon/GLP-1 receptor agonist, compared with placebo and open-label semaglutide in people with type 2 diabetes: a randomised clinical trial;Diabetologia;2023-12-14

2. Determinants of plasma levels of gcg and metabolic impact of glucagon receptor signalling – a UK Biobank study;2023-12-14

3. Results from three phase 1 trials of NNC9204-1177, a glucagon/GLP-1 receptor co-agonist: Effects on weight loss and safety in adults with overweight or obesity;Molecular Metabolism;2023-12

4. Glucagon and energy expenditure; Revisiting amino acid metabolism and implications for weight loss therapy;Peptides;2023-04

5. Opposing effects of chronic glucagon receptor agonism and antagonism on amino acids, hepatic gene expression, and alpha cells;iScience;2022-11